Senator John Fetterman from Pennsylvania recently shared his personal experience with Mounjaro, a GLP-1 drug traditionally used for type 2 diabetes. In his op-ed in The New York Times, he explained how taking the medication has drastically improved his health. Initially prescribed for its potential to reduce major cardiac events, the drug ended up making him feel significantly better overall.
Fetterman was particularly impressed by how the aches and pains he once felt had disappeared. He noted feeling a decade younger, both physically and mentally, and reported losing around 20 pounds as a side effect. The senator is now advocating for broader access to these anti-obesity medications, which have shown benefits beyond just lowering blood sugar.
Eli Lilly, the company behind Mounjaro, also produces Zepbound, a version approved for weight loss and chronic weight management. Other similar medications like Ozempic and Wegovy are manufactured by Novo Nordisk. These drugs have been reported to improve heart health, neurological function, and metabolic health, according to Fox News Digital.
In his article, Fetterman emphasized that GLP-1 drugs have a positive impact on cholesterol, heart rate, and inflammation. Some studies even suggest they could help with alcohol addiction and cognitive functions, potentially slowing diseases like Parkinson’s and Alzheimer’s. He’s pushing for these medications to be more accessible, as they can cost up to $1,000 without insurance coverage.
Currently, Medicare and Medicaid have limited coverage for these drugs, focusing mostly on diabetes and high heart risk cases. Fetterman wants to change that, stating that he’s just someone who’s benefited from these medications and wishes others could too. He aligns with the belief that while diet and lifestyle are important, medication can be an essential first step for those dealing with significant health issues.
Dr. Marc Siegel, a medical analyst for Fox News, acknowledges the growing importance of GLP-1 medications in treating both diabetes and obesity. He pointed out that while lifestyle changes are the first step, these drugs are valuable tools when those changes aren’t enough. Siegel also believes expanding Medicare and Medicaid coverage could save the healthcare system money in the long run.
Dr. Brett Osborn, a neurologist, has been prescribing GLP-1 drugs since 2019 and refers to them as a “metabolic reset button.” He stresses that while lifestyle changes are crucial, they’re not always sufficient. GLP-1 drugs can help people start forming healthier habits by providing an initial boost.
These medications are not just for cosmetic purposes, Osborn explained, but are therapeutic in reducing body fat, inflammation, and the risk of stroke and heart attack. He believes that President Trump’s administration decision not to cover these drugs under Medicare and Medicaid is more about negotiating lower prices with Big Pharma than doubting the drugs’ effectiveness.
Osborn thinks Trump’s move is a strategic one, aimed at encouraging pharmaceutical companies to reduce their prices. By leveraging Medicare’s buying power, the goal is to make these medications more affordable while still improving the health of Americans.
